Hepatitis

Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…

Technologies to prevent, detect, and treat viral hepatitis have advanced considerably in recent decades, but the number of people dying from these infections continues…

The U.S. Food and Drug Administration (FDA) has again expanded its approval of Gilead Sciences’ medication Vemlidy (tenofovir alafenamide) for chronic hepatitis B…

Researchers have identified new strategies for developing a vaccine against hepatitis C by studying the immune responses of a patient who spontaneously cleared three…

The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help diagnosed but untreated hepatitis…

Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…

A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…

While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…

The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…

Community-based organizations in Canada addressing hepatitis C, the human immunodeficiency virus (HIV), and other sexually transmitted and blood-borne infections (STBBIs) will receive more than…